Cargando…

Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial

BACKGROUND: Cancer is one of the major health issues worldwide. An increasing number of cancer patients are offered treatment with surgery, chemotherapy and radiotherapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies offered to cancer patients in Taiwan. We des...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Lun-Chien, Chen, Chia-Yun, Chen, Shou-Tung, Chen, Hung-Chang, Lee, Tsung-Chieh, Chang, Cheng-Shyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543266/
https://www.ncbi.nlm.nih.gov/pubmed/23206440
http://dx.doi.org/10.1186/1745-6215-13-232
_version_ 1782255628761169920
author Lo, Lun-Chien
Chen, Chia-Yun
Chen, Shou-Tung
Chen, Hung-Chang
Lee, Tsung-Chieh
Chang, Cheng-Shyong
author_facet Lo, Lun-Chien
Chen, Chia-Yun
Chen, Shou-Tung
Chen, Hung-Chang
Lee, Tsung-Chieh
Chang, Cheng-Shyong
author_sort Lo, Lun-Chien
collection PubMed
description BACKGROUND: Cancer is one of the major health issues worldwide. An increasing number of cancer patients are offered treatment with surgery, chemotherapy and radiotherapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies offered to cancer patients in Taiwan. We designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of TCM in patients with cancer. METHODS/DESIGN: In this study, inclusion criteria are postoperative patients with histologically confirmed cancer within 3 years who are undergoing chemotherapy or radiotherapy, more than 18 years old, have given signed informed consent, have the ability to read Chinese, and the ability for oral intake. Exclusion criteria include being pregnant, breast feeding, having completed chemotherapy or radiotherapy, brain metastasis with Eastern Cooperative Oncology Group (ECOG) performance status of two to four, delusion or hallucinations, acute infection, and have received medications under other clinical trials. The patients were separated into an intervention group (Shen-Mai-San, SMS) and a placebo group for four weeks using a randomized, double-blind procedure. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QOL-C30) was used to evaluate the quality of life. General data, hemoglobin (Hb), hematocrit (Hct), glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine, carcinoembryonic antigen (CEA), TCM diagnosis data and heart rate variability (HRV) were also recorded. These data were collected at baseline, two weeks and four weeks after receiving medication. The patients were prescribed granules which contained therapeutic medicines or placebo. Paired-T test was used for statistical analysis. DISCUSSION: Shen-Mai-San is composed of processed Ginseng radis, Liriope spicata, and Schizandrae fructus. It was found to be effective for treating cancer-related fatigue and had anti-fatigue activity. In TCM theory, SMS has a synergistic effect for qi and yin deficiency and has the ability to prevent fatigue. The symptoms of qi and yin deficiency are similar to chemotherapy- or radiotherapy-induced side effects. In order to evaluate the efficacy of SMS on cancer treatment, we designed a randomized, double-blind, placebo-controlled trial. TRIAL REGISTRATION: This study is registered to Clinical Trails.gov NCT01580358
format Online
Article
Text
id pubmed-3543266
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35432662013-01-14 Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial Lo, Lun-Chien Chen, Chia-Yun Chen, Shou-Tung Chen, Hung-Chang Lee, Tsung-Chieh Chang, Cheng-Shyong Trials Study Protocol BACKGROUND: Cancer is one of the major health issues worldwide. An increasing number of cancer patients are offered treatment with surgery, chemotherapy and radiotherapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies offered to cancer patients in Taiwan. We designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of TCM in patients with cancer. METHODS/DESIGN: In this study, inclusion criteria are postoperative patients with histologically confirmed cancer within 3 years who are undergoing chemotherapy or radiotherapy, more than 18 years old, have given signed informed consent, have the ability to read Chinese, and the ability for oral intake. Exclusion criteria include being pregnant, breast feeding, having completed chemotherapy or radiotherapy, brain metastasis with Eastern Cooperative Oncology Group (ECOG) performance status of two to four, delusion or hallucinations, acute infection, and have received medications under other clinical trials. The patients were separated into an intervention group (Shen-Mai-San, SMS) and a placebo group for four weeks using a randomized, double-blind procedure. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QOL-C30) was used to evaluate the quality of life. General data, hemoglobin (Hb), hematocrit (Hct), glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine, carcinoembryonic antigen (CEA), TCM diagnosis data and heart rate variability (HRV) were also recorded. These data were collected at baseline, two weeks and four weeks after receiving medication. The patients were prescribed granules which contained therapeutic medicines or placebo. Paired-T test was used for statistical analysis. DISCUSSION: Shen-Mai-San is composed of processed Ginseng radis, Liriope spicata, and Schizandrae fructus. It was found to be effective for treating cancer-related fatigue and had anti-fatigue activity. In TCM theory, SMS has a synergistic effect for qi and yin deficiency and has the ability to prevent fatigue. The symptoms of qi and yin deficiency are similar to chemotherapy- or radiotherapy-induced side effects. In order to evaluate the efficacy of SMS on cancer treatment, we designed a randomized, double-blind, placebo-controlled trial. TRIAL REGISTRATION: This study is registered to Clinical Trails.gov NCT01580358 BioMed Central 2012-12-03 /pmc/articles/PMC3543266/ /pubmed/23206440 http://dx.doi.org/10.1186/1745-6215-13-232 Text en Copyright ©2012 Lo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Lo, Lun-Chien
Chen, Chia-Yun
Chen, Shou-Tung
Chen, Hung-Chang
Lee, Tsung-Chieh
Chang, Cheng-Shyong
Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
title Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
title_full Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
title_fullStr Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
title_full_unstemmed Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
title_short Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
title_sort therapeutic efficacy of traditional chinese medicine, shen-mai san, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543266/
https://www.ncbi.nlm.nih.gov/pubmed/23206440
http://dx.doi.org/10.1186/1745-6215-13-232
work_keys_str_mv AT lolunchien therapeuticefficacyoftraditionalchinesemedicineshenmaisanincancerpatientsundergoingchemotherapyorradiotherapystudyprotocolforarandomizeddoubleblindplacebocontrolledtrial
AT chenchiayun therapeuticefficacyoftraditionalchinesemedicineshenmaisanincancerpatientsundergoingchemotherapyorradiotherapystudyprotocolforarandomizeddoubleblindplacebocontrolledtrial
AT chenshoutung therapeuticefficacyoftraditionalchinesemedicineshenmaisanincancerpatientsundergoingchemotherapyorradiotherapystudyprotocolforarandomizeddoubleblindplacebocontrolledtrial
AT chenhungchang therapeuticefficacyoftraditionalchinesemedicineshenmaisanincancerpatientsundergoingchemotherapyorradiotherapystudyprotocolforarandomizeddoubleblindplacebocontrolledtrial
AT leetsungchieh therapeuticefficacyoftraditionalchinesemedicineshenmaisanincancerpatientsundergoingchemotherapyorradiotherapystudyprotocolforarandomizeddoubleblindplacebocontrolledtrial
AT changchengshyong therapeuticefficacyoftraditionalchinesemedicineshenmaisanincancerpatientsundergoingchemotherapyorradiotherapystudyprotocolforarandomizeddoubleblindplacebocontrolledtrial